On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) oral Fabhalta (iptacopan) for adults with C3 glomerulopathy (C3G) to reduce proteinuria (protein in the ...

A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full FDA approval, strengthening the product’s case to compete against two other ...

Novartis’s iptacopan met the first of two main goals in its pivotal study in immunoglobulin A nephropathy, and the pharma giant plans to seek accelerated FDA approval next year. The drug could ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.

Novartis wins FDA approval for the label expansion of Fabhalta for a third indication ... FDA Approves Novartis Drug for Rare Kidney Disease Treatment March 21, 2025 — 02:10 pm EDT.

On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...

FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease. On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first ...

Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression.